Dr. Rayson is a medical oncologist and professor in the Division of Medical Oncology. He is director of the Atlantic Clinical Cancer Research Unit (ACCRU), a Beatrice Hunter Cancer Research Institute (BHCRI) senior scientist and a principle investigator and steering committee member with the Canadian Cancer Clinical Trial Network (CCCTN) as well as the Halifax Centre Representative at the National Cancer Institute of Canada (NCIC)

Dr. Rayson’s research interests are in: clinical trials in breast cancer and gastrointestinal neuroendocrine tumors breast cancer care path analysis interval and triple-negative breast cancer economic analysis of new cancer therapies translational and clinical research in gastrointestinal neuroendocrine tumors

Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels. Lamond NW, Skedgel C, Rayson D, Younis T. Curr Oncol. 2015 Aug;22(4):e246-53. doi:10.3747/co.22.2383. Investigations for patients with early-stage breast cancer: Oversetting the stage. Rayson D, Porter G. CMAJ. 2015 Sep 8;187(12):860-1. Trastuzumab beyond progression for HER2 positive metastatic breast cancer: Progression-free survival on first-line therapy predicts overall survival impact. Rayson D, Lutes S, Walsh G, Sellon M, Colwell B, Dorreen M, Drucker A, Jeyakumar A, Younis T The Breast J 2014;20(4):408-413. Reflections on In-Patient Palliative Chemotherapy: Is There Ever a Right Place at the Right Time. Rayson D, Kain Danielle. Curr Oncol. 2014;21(4):158-60. Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: A population-based analysis. Rayson D, Urquhart R, Cox M, Grunfeld E, Porter G. J Oncol Pract 2012 Jul;8(4): 253–259.